Bruce N Cronstein

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4452490/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Selfâ€assembling human skeletal organoids for disease modeling and drug testing. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2022, 110, 871-884.	3.4	14
2	Tissue Engineering Strategies for Craniomaxillofacial Surgery: Current Trends in 3D-Printed Bioactive Ceramic Scaffolds. Springer Series in Biomaterials Science and Engineering, 2022, , 55-74.	1.0	2
3	International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update. Pharmacological Reviews, 2022, 74, 340-372.	16.0	67
4	Annexin A2-Mediated Plasminogen Activation in Endothelial Cells Contributes to the Proangiogenic Effect of Adenosine A2A Receptors. Frontiers in Pharmacology, 2021, 12, 654104.	3.5	10
5	Adenosine A2A receptor null chondrocyte transcriptome resembles that of human osteoarthritic chondrocytes. Purinergic Signalling, 2021, 17, 439-448.	2.2	3
6	Ticagrelor added to methotrexate improves rheumatoid arthritis disease severity. Rheumatology, 2021, 60, 5473-5475.	1.9	3
7	Browning of adipose tissue and increased thermogenesis induced by Methotrexate. FASEB BioAdvances, 2021, 3, 877-887.	2.4	2
8	ATP transporters in the joints. Purinergic Signalling, 2021, 17, 591-605.	2.2	7
9	Adenosine A2A receptor signaling promotes FoxO associated autophagy in chondrocytes. Scientific Reports, 2021, 11, 968.	3.3	18
10	Transforming the Degradation Rate of β-tricalcium Phosphate Bone Replacement Using 3-Dimensional Printing. Annals of Plastic Surgery, 2021, 87, e153-e162.	0.9	12
11	SLE and purine metabolizing ecto-enzymes. EBioMedicine, 2021, 74, 103688.	6.1	0
12	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019. Annals of the Rheumatic Diseases, 2020, 79, 88-93.	0.9	63
13	Mécanisme d'action du méthotrexate dans le traitement de la polyarthrite rhumatoÃ⁻de. Revue Du Rhumatisme (Edition Francaise), 2020, 87, 92-98.	0.0	0
14	Bone Tissue Engineering in the Growing Calvaria Using Dipyridamole-Coated, Three-Dimensionally–Printed Bioceramic Scaffolds: Construct Optimization and Effects on Cranial Suture Patency. Plastic and Reconstructive Surgery, 2020, 145, 337e-347e.	1.4	30
15	Effects of Acute Colchicine Administration Prior to Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2020, 13, e008717.	3.9	115
16	Methotrexate and its mechanisms of action in inflammatory arthritis. Nature Reviews Rheumatology, 2020, 16, 145-154.	8.0	321
17	Adenosine A2A receptor (A2AR) stimulation enhances mitochondrial metabolism and mitigates reactive oxygen speciesâ€mediated mitochondrial injury. FASEB Journal, 2020, 34, 5027-5045.	0.5	35
18	Gerald Weissmann: Inflammation in rheumatic disease. Annals of the Rheumatic Diseases, 2020, 79, 435-436	0.9	1

#	Article	IF	CITATIONS
19	Profiling Clinical Research Activity at an Academic Medical Center by Using Institutional Databases: Content Analysis. JMIR Public Health and Surveillance, 2020, 6, e12813.	2.6	1
20	Local delivery of adenosine receptor agonists to promote bone regeneration and defect healing. Advanced Drug Delivery Reviews, 2019, 146, 240-247.	13.7	25
21	Repair of Criticalâ€Sized Long Bone Defects Using Dipyridamoleâ€Augmented 3Dâ€Printed Bioactive Ceramic Scaffolds. Journal of Orthopaedic Research, 2019, 37, 2499-2507.	2.3	33
22	Come from away: Best practices in mini-sabbaticals for the development of young investigators: a White Paper by the SEQUIN (mini-Sabbatical Evaluation and QUality ImprovemeNt) Group. Journal of Clinical and Translational Science, 2019, 3, 37-44.	0.6	4
23	Tissue-engineered alloplastic scaffolds for reconstruction of alveolar defects. , 2019, , 505-520.		3
24	Adenosine-Functionalized Biodegradable PLA-b-PEG Nanoparticles Ameliorate Osteoarthritis in Rats. Scientific Reports, 2019, 9, 7430.	3.3	30
25	Adenosine A _{2A} receptor (A2AR) activation triggers Akt signaling and enhances nuclear localization of βâ€eatenin in osteoblasts. FASEB Journal, 2019, 33, 7555-7562.	0.5	16
26	3D Printing and Adenosine Receptor Activation for Craniomaxillofacial Regeneration. , 2019, , 255-267.		2
27	Regeneration of a Pediatric Alveolar Cleft Model Using Three-Dimensionally Printed Bioceramic Scaffolds and Osteogenic Agents: Comparison of Dipyridamole and rhBMP-2. Plastic and Reconstructive Surgery, 2019, 144, 358-370.	1.4	21
28	Dipyridamole-loaded 3D-printed bioceramic scaffolds stimulate pediatric bone regeneration in vivo without disruption of craniofacial growth through facial maturity. Scientific Reports, 2019, 9, 18439.	3.3	29
29	Dipyridamole Augments Three-Dimensionally Printed Bioactive Ceramic Scaffolds to Regenerate Craniofacial Bone. Plastic and Reconstructive Surgery, 2019, 143, 1408-1419.	1.4	22
30	Tenofovir Causes Bone Loss via Decreased Bone Formation and Increased Bone Resorption, Which Can Be Counteracted by Dipyridamole in Mice. Journal of Bone and Mineral Research, 2019, 34, 923-938.	2.8	26
31	Methotrexate mechanism in treatment of rheumatoid arthritis. Joint Bone Spine, 2019, 86, 301-307.	1.6	239
32	Signaling of the Purinergic System in the Joint. Frontiers in Pharmacology, 2019, 10, 1591.	3.5	14
33	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. Annals of the Rheumatic Diseases, 2019, 78, 872-878.	0.9	36
34	A tribute to Gerald Weissmann (1930–2019). Journal of Clinical Investigation, 2019, 129, 4553-4555.	8.2	0
35	The Role of Adenosine Receptor Activation in Attenuating Cartilaginous Inflammation. Inflammation, 2018, 41, 1135-1141.	3.8	14
36	Adenosine metabolism, immunity and joint health. Biochemical Pharmacology, 2018, 151, 307-313.	4.4	54

#	Article	IF	CITATIONS
37	Augmented Th17 Differentiation Leads to Cutaneous and Synovioâ€Entheseal Inflammation in a Novel Model of Psoriatic Arthritis. Arthritis and Rheumatology, 2018, 70, 855-867.	5.6	29
38	Dipyridamole enhances osteogenesis of three-dimensionally printed bioactive ceramic scaffolds in calvarial defects. Journal of Cranio-Maxillo-Facial Surgery, 2018, 46, 237-244.	1.7	44
39	Three dimensionally printed bioactive ceramic scaffold osseoconduction across critical-sized mandibular defects. Journal of Surgical Research, 2018, 223, 115-122.	1.6	67
40	Teaching Targeted Drug Discovery and Development to Healthcare Professionals. Clinical and Translational Science, 2018, 11, 277-282.	3.1	3
41	Blockade of the Adenosine 2A Receptor Mitigates the Cardiomyopathy Induced by Loss of Plakophilin-2 Expression. Frontiers in Physiology, 2018, 9, 1750.	2.8	11
42	The role of 3D printing in treating craniomaxillofacial congenital anomalies. Birth Defects Research, 2018, 110, 1055-1064.	1.5	40
43	Adenosine A _{2A} receptor (A2AR) stimulation modulates expression of semaphorins 4D and 3A, regulators of bone homeostasis. FASEB Journal, 2018, 32, 3487-3501.	0.5	29
44	Form and functional repair of long bone using 3Dâ€printed bioactive scaffolds. Journal of Tissue Engineering and Regenerative Medicine, 2018, 12, 1986-1999.	2.7	49
45	Methotrexate BAFFles anti-drug antibodies. Nature Reviews Rheumatology, 2018, 14, 505-506.	8.0	7
46	Bone regeneration in critical bone defects using threeâ€dimensionally printed βâ€tricalcium phosphate/hydroxyapatite scaffolds is enhanced by coating scaffolds with either dipyridamole or BMPâ€2. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2017, 105, 366-375.	3.4	110
47	Endogenous adenosine maintains cartilage homeostasis and exogenous adenosine inhibits osteoarthritis progression. Nature Communications, 2017, 8, 15019.	12.8	91
48	Ecto-5′-nucleotidase (CD73) regulates bone formation and remodeling during intramembranous bone repair in aging mice. Tissue and Cell, 2017, 49, 545-551.	2.2	22
49	Adenosine A2a Receptor Blockade Diminishes Wnt/β-Catenin Signaling in a Murine Model of Bleomycin-Induced Dermal Fibrosis. American Journal of Pathology, 2017, 187, 1935-1944.	3.8	33
50	Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases. Nature Reviews Rheumatology, 2017, 13, 41-51.	8.0	189
51	OP0186â€Tenofovir, a nucleoside analog reverse transcriptase inhibitor for treatment of hiv, promotes osteoclast differentiation and bone lost in vivo in a mechanism depending on atp release and adenosine, and dipyridamole may be a useful treatment to revert the effects. , 2017, , .		0
52	The antiviral drug tenofovir, an inhibitor of Pannexin-1-mediated ATP release, prevents liver and skin fibrosis by downregulating adenosine levels in the liver and skin. PLoS ONE, 2017, 12, e0188135.	2.5	32
53	Growth Hormone Control of Hepatic Lipid Metabolism. Diabetes, 2016, 65, 3598-3609.	0.6	90
54	Adenosine A _{2A} receptor promotes collagen type III synthesis via β atenin activation in human dermal fibroblasts. British Journal of Pharmacology, 2016, 173, 3279-3291.	5.4	29

#	Article	IF	CITATIONS
55	Regulation of bone and cartilage by adenosine signaling. Purinergic Signalling, 2016, 12, 583-593.	2.2	43
56	Netrinâ€1 and its receptor Unc5b are novel targets for the treatment of inflammatory arthritis. FASEB Journal, 2016, 30, 3835-3844.	0.5	25
57	Ticagrelor regulates osteoblast and osteoclast function and promotes bone formation in vivo <i>via</i> an adenosineâ€dependent mechanism. FASEB Journal, 2016, 30, 3887-3900.	0.5	49
58	Adenosine A2B receptors play an important role in bone homeostasis. Purinergic Signalling, 2016, 12, 537-547.	2.2	32
59	Signaling pathways involving adenosine A2A and A2B receptors in wound healing and fibrosis. Purinergic Signalling, 2016, 12, 191-197.	2.2	55
60	Adenosine A2A receptor plays an important role in radiationâ€induced dermal injury. FASEB Journal, 2016, 30, 457-465.	0.5	28
61	Netrin-1 is highly expressed and required in inflammatory infiltrates in wear particle-induced osteolysis. Annals of the Rheumatic Diseases, 2016, 75, 1706-1713.	0.9	26
62	Purinergic signaling in scarring. FASEB Journal, 2016, 30, 3-12.	0.5	65
63	Ticagrelor Modulates Proliferation in Multiple Myeloma Via P1 and P2 Receptor-Mediated Mechanisms. Blood, 2016, 128, 5694-5694.	1.4	Ο
64	Teaching Translational Research to Medical Students: The New York University School of Medicine's Master's of Science in Clinical Investigation Dualâ€Degree Program. Clinical and Translational Science, 2015, 8, 734-739.	3.1	11
65	Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors. Arthritis Research and Therapy, 2015, 17, 249.	3.5	63
66	Clinical trial development for biosimilars. Seminars in Arthritis and Rheumatism, 2015, 44, S2-S8.	3.4	70
67	Promotion of Wound Healing by an Agonist of Adenosine A2A Receptor Is Dependent on Tissue Plasminogen Activator. Inflammation, 2015, 38, 2036-2041.	3.8	20
68	Direct or indirect stimulation of adenosine A _{2A} receptors enhances bone regeneration as well as bone morphogenetic proteinâ€2. FASEB Journal, 2015, 29, 1577-1590.	0.5	81
69	Brief Report: Methotrexate Prevents Wear Particle–Induced Inflammatory Osteolysis in Mice Via Activation of Adenosine A _{2A} Receptor. Arthritis and Rheumatology, 2015, 67, 849-855.	5.6	20
70	Netrin-1 Is a Critical Autocrine/Paracrine Factor for Osteoclast Differentiation. Journal of Bone and Mineral Research, 2015, 30, 837-854.	2.8	48
71	Netrin-1 and Its Receptors Unc5b and DCC May be Useful Targets for Preventing Multiple Myeloma Bone Lesions. Blood, 2015, 126, 1815-1815.	1.4	1
72	Pharmacogenomics in rheumatology. , 2015, , 406-409.		0

Pharmacogenomics in rheumatology. , 2015, , 406-409. 72

#	Article	IF	CITATIONS
73	Outcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature review. Clinical and Experimental Rheumatology, 2015, 33, 272-8.	0.8	30
74	The benefits and drawbacks of biosimilars. Clinical Advances in Hematology and Oncology, 2015, 13, 639-41.	0.3	0
75	Adenosine 2A receptor promotes collagen production by human fibroblasts <i>via</i> pathways involving cyclic AMP and AKT but independent of Smad2/3. FASEB Journal, 2014, 28, 802-812.	0.5	63
76	Designing and Implementing INTREPID, an Intensive Program in Translational Research Methodologies for New Investigators. Clinical and Translational Science, 2014, 7, 493-499.	3.1	8
77	Activation of EPAC1/2 is essential for osteoclast formation by modulating NFκB nuclear translocation and actin cytoskeleton rearrangements. FASEB Journal, 2014, 28, 4901-4913.	0.5	39
78	Adenosine A2A receptors promote collagen production by a Fli1- and CTGF-mediated mechanism. Arthritis Research and Therapy, 2013, 15, R58.	3.5	38
79	The Adenosine-Dependent Angiogenic Switch of Macrophages to an M2-Like Phenotype is Independent of Interleukin-4 Receptor Alpha (IL-4Rα) Signaling. Inflammation, 2013, 36, 921-931.	3.8	262
80	Adenosine regulates bone metabolism <i>via</i> A ₁ , A _{2A} , and A _{2B} receptors in bone marrow cells from normal humans and patients with multiple myeloma. FASEB Journal, 2013, 27, 3446-3454.	0.5	64
81	Adenosine A2A receptor (A2AR) is a fine-tune regulator of the collagen1:collagen3 balance. Purinergic Signalling, 2013, 9, 573-583.	2.2	30
82	Extracellular Generation of Adenosine by the Ectonucleotidases CD39 and CD73 Promotes Dermal Fibrosis. American Journal of Pathology, 2013, 183, 1740-1746.	3.8	46
83	Adenosine and bone metabolism. Trends in Endocrinology and Metabolism, 2013, 24, 290-300.	7.1	110
84	Adenosine A2A Receptor and TNF-α Regulate the Circadian Machinery of the Human Monocytic THP-1 Cells. Inflammation, 2013, 36, 152-162.	3.8	27
85	Activation of adenosine <scp>A_{2A}</scp> receptor reduces osteoclast formation via <scp>PKA</scp> â€and <scp>ERK1</scp> /2â€mediated suppression of <scp>NF</scp> î° <scp>B</scp> nuclear translocation. British Journal of Pharmacology, 2013, 169, 1372-1388.	5.4	72
86	Regulation of Inflammation by Adenosine. Frontiers in Immunology, 2013, 4, 85.	4.8	272
87	Mechanistic Aspects of Inflammation and Clinical Management of Inflammation in Acute Gouty Arthritis. Journal of Clinical Rheumatology, 2013, 19, 19-29.	0.9	105
88	Greater Number of Narcotic Analgesic Prescriptions for Osteoarthritis Is Associated with Falls and Fractures in Elderly Adults. Journal of the American Geriatrics Society, 2013, 61, 335-340.	2.6	130
89	Rolofylline, an adenosine <scp>A₁</scp> receptor antagonist, inhibits osteoclast differentiation as an inverse agonist. British Journal of Pharmacology, 2013, 170, 1167-1176.	5.4	21
90	Fibroblasts from methotrexate-sensitive mice accumulate methotrexate polyglutamates but those from methotrexate-resistant mice do not. Clinical and Experimental Rheumatology, 2013, 31, 433-5.	0.8	7

#	Article	IF	CITATIONS
91	Adenosine A _{2A} Receptor Activation Prevents Wear Particle–Induced Osteolysis. Science Translational Medicine, 2012, 4, 135ra65.	12.4	68
92	Colchicine Use Is Associated with Decreased Prevalence of Myocardial Infarction in Patients with Gout. Journal of Rheumatology, 2012, 39, 1458-1464.	2.0	173
93	Regulation of Foam Cells by Adenosine. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 879-886.	2.4	51
94	Adenosine A2A Receptor Ligation Inhibits Osteoclast Formation. American Journal of Pathology, 2012, 180, 775-786.	3.8	83
95	Pharmacological blockade of adenosine A _{2A} receptors diminishes scarring. FASEB Journal, 2012, 26, 4254-4263.	0.5	38
96	The Effect of A2A Adenosine Receptor Activation on C-C Chemokine Receptor 7 Expression in Human THP1 Macrophages During Inflammation. Inflammation, 2012, 35, 614-622.	3.8	13
97	Preparedness of the CTSA's Structural and Scientific Assets to Support the Mission of the National Center for Advancing Translational Sciences (NCATS). Clinical and Translational Science, 2012, 5, 121-129.	3.1	20
98	A Public-Private Partnership: The New York University-Health and Hospitals Corporation Clinical and Translational Science Institute. Clinical and Translational Science, 2012, 5, 223-225.	3.1	1
99	Cholesterol 27-Hydroxylase but Not Apolipoprotein apoE Contributes to A2A Adenosine Receptor Stimulated Reverse Cholesterol Transport. Inflammation, 2012, 35, 49-57.	3.8	14
100	Adenosine Regulates Bone Metabolism Via A1, A2A and A2B Receptors in Bone Marrow Cells From Normal and Patients with Multiple Myeloma. Blood, 2012, 120, 4977-4977.	1.4	0
101	The roles of adenosine and adenosine receptors in bone remodeling. Frontiers in Bioscience - Elite, 2011, E3, 888-895.	1.8	10
102	Restraint stress fails to modulate cutaneous hypersensitivity responses in mice lacking the adenosine A1 receptor. Purinergic Signalling, 2011, 7, 47-56.	2.2	4
103	Biosimilars: The debate continues. Arthritis and Rheumatism, 2011, 63, 2848-2850.	6.7	27
104	Immune Responses Associated With Perioperative Exposure and Reexposure to Topical Bovine Thrombin Do Not Impair Hemostasis. Clinical and Applied Thrombosis/Hemostasis, 2011, 17, 620-632.	1.7	6
105	Methylxanthines and Inflammatory Cells. Handbook of Experimental Pharmacology, 2011, , 457-468.	1.8	13
106	Adenosine receptors and fibrosis: a translational review. F1000 Biology Reports, 2011, 3, 21.	4.0	59
107	Plasma from systemic lupus patients compromises cholesterol homeostasis: a potential mechanism linking autoimmunity to atherosclerotic cardiovascular disease. Rheumatology International, 2010, 30, 591-598.	3.0	22
108	Interest in Conflicts. Clinical and Translational Science, 2010, 3, 52-53.	3.1	0

#	Article	IF	CITATIONS
109	Adenosine A ₁ receptors regulate bone resorption in mice: Adenosine A ₁ receptor blockade or deletion increases bone density and prevents ovariectomyâ€induced bone loss in adenosine A ₁ receptor–knockout mice. Arthritis and Rheumatism, 2010, 62, 534-541.	6.7	79
110	Interferon-gamma inhibits adenosine A2A receptor function in hepatic stellate cells by STAT1-mediated repression of adenylyl cyclase. International Journal of Interferon, Cytokine and Mediator Research, 2010, 2010, 113.	1.1	9
111	Adenosine A ₁ receptors (A ₁ Rs) play a critical role in osteoclast formation and function. FASEB Journal, 2010, 24, 2325-2333.	0.5	73
112	Drs. Fisher and Cronstein reply. Journal of Rheumatology, 2010, 37, 1065.1-1065.	2.0	0
113	Adenosine in fibrosis. Modern Rheumatology, 2010, 20, 114-122.	1.8	35
114	Adenosine A _{2A} receptor activation protects CD4 ⁺ T lymphocytes against activationâ€induced cell death. FASEB Journal, 2010, 24, 2631-2640.	0.5	66
115	A2A adenosine receptor stimulation decreases foam cell formation by enhancing ABCA1-dependent cholesterol efflux. Journal of Leukocyte Biology, 2010, 87, 683-690.	3.3	38
116	Caffeine, a drug for all seasons. Journal of Hepatology, 2010, 53, 207-208.	3.7	14
117	Methotrexate—how does it really work?. Nature Reviews Rheumatology, 2010, 6, 175-178.	8.0	332
118	A personal journey from the joint to the heart. Arthritis Research and Therapy, 2010, 12, 134.	3.5	3
119	Adenosine in fibrosis. Modern Rheumatology, 2010, 20, 114-122.	1.8	29
120	Immune Response Following Exposures to Topical Bovine Thrombin Does Not Impair Hemostasis. Blood, 2010, 116, 1401-1401.	1.4	2
121	Adenosine A2A receptors play an active role in mouse bone marrow-derived mesenchymal stem cell development. Journal of Leukocyte Biology, 2009, 85, 438-444.	3.3	77
122	Adenosine receptor agonists for promotion of dermal wound healing. Biochemical Pharmacology, 2009, 77, 1117-1124.	4.4	90
123	Metaanalysis of Methylenetetrahydrofolate Reductase (MTHFR) Polymorphisms Affecting Methotrexate Toxicity. Journal of Rheumatology, 2009, 36, 539-545.	2.0	100
124	CD4+CD25+ regulatory T cells suppress contact hypersensitivity reactions through a CD39, adenosine-dependent mechanism. Journal of Allergy and Clinical Immunology, 2009, 123, 1287-1296.e2.	2.9	96
125	Rheumatoid arthritis: GWAS or TMI?. Genome Medicine, 2009, 1, 98.	8.2	0
126	A BRIEF COMMUNICATION. Experimental Biology and Medicine, 2009, 234, 354-360.	2.4	29

#	Article	IF	CITATIONS
127	Adenosine Receptors in Wound Healing, Fibrosis and Angiogenesis. Handbook of Experimental Pharmacology, 2009, , 383-397.	1.8	62
128	Adenosine signaling contributes to ethanol-induced fatty liver in mice. Journal of Clinical Investigation, 2009, 119, 582-594.	8.2	152
129	The Clinical Features of Gout. , 2009, , 351-354.		0
130	Something old, something newcolchicine in the 21st century. Current Opinion in Investigational Drugs, 2009, 10, 1141-2.	2.3	1
131	Adenosine A2A Receptor Blockade or Deletion Diminishes Fibrocyte Accumulation in the Skin in a Murine Model of Scleroderma, Bleomycin-induced Fibrosis. Inflammation, 2008, 31, 299-303.	3.8	41
132	Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THPâ€1 monocyte/macrophages. Arthritis and Rheumatism, 2008, 58, 3675-3683.	6.7	142
133	Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nature Reviews Drug Discovery, 2008, 7, 759-770.	46.4	990
134	Bovine Thrombin and the Clinical Consequence of Antibody Development. Journal of the American College of Surgeons, 2008, 206, 199.	0.5	1
135	Pharmacological Blockade of A2A Receptors Prevents Dermal Fibrosis in a Model of Elevated Tissue Adenosine. American Journal of Pathology, 2008, 172, 1675-1682.	3.8	58
136	Ectoâ€5′â€nucleotidase (CD73) â€mediated extracellular adenosine production plays a critical role in hepatic fibrosis. FASEB Journal, 2008, 22, 2263-2272.	0.5	105
137	Ecto-5′-Nucleotidase (Cd73)-Mediated Extracellular Adenosine Production Plays a Critical Role in Hepatic Fibrosis. Nucleosides, Nucleotides and Nucleic Acids, 2008, 27, 821-824.	1.1	19
138	Immunomodulating pharmaceuticals. , 2008, , 1331-1339.		0
139	Molecular Mechanisms Involved in Adenosine Receptorâ€mediated Suppression of Foam Cell Formation. FASEB Journal, 2008, 22, 1129.21.	0.5	0
140	Requirements for T Lymphocyte Migration in Explanted Lymph Nodes. Journal of Immunology, 2007, 178, 7747-7755.	0.8	127
141	Do elevated red blood cell methotrexate polyglutamate levels predict methotrexate efficacy?. Nature Clinical Practice Rheumatology, 2007, 3, 256-257.	3.2	1
142	Methotrexate in rheumatoid arthritis. Expert Review of Clinical Immunology, 2007, 3, 27-33.	3.0	8
143	Adenosine and Inflammation. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2007, 7, 280-285.	0.5	1
144	Adenosine A _{2A} Receptor Occupancy Stimulates Collagen Expression by Hepatic Stellate Cells via Pathways Involving Protein Kinase A, Src, and Extracellular Signal-Regulated Kinases 1/2 Signaling Cascade or p38 Mitogen-Activated Protein Kinase Signaling Pathway. Molecular Pharmacology, 2007, 72, 1626-1636.	2.3	97

#	Article	IF	CITATIONS
145	Adenosine receptor activation ameliorates type 1 diabetes. FASEB Journal, 2007, 21, 2379-2388.	0.5	93
146	5-Aminoimidazole-4-Carboxamide-1-β-4-Ribofuranoside (AICA-riboside) as a Targeting Agent for Therapy of Patients With Acute Lymphoblastic Leukemia: Are We There and Are There Pitfalls?. Journal of Pediatric Hematology/Oncology, 2007, 29, 805-807.	0.6	9
147	Wound Healing Is Impaired in MyD88-Deficient Mice. American Journal of Pathology, 2007, 171, 1774-1788.	3.8	139
148	The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5′-nucleotidase: Findings in a study of ecto-5′-nucleotidase gene–deficient mice. Arthritis and Rheumatism, 2007, 56, 1440-1445.	6.7	131
149	Adenosine in inflammatory joint diseases. Purinergic Signalling, 2007, 3, 145-152.	2.2	19
150	Interleukin-6a key mediator of systemic and local symptoms in rheumatoid arthritis. Bulletin of the NYU Hospital for Joint Diseases, 2007, 65 Suppl 1, S11-5.	0.7	44
151	Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bulletin of the NYU Hospital for Joint Diseases, 2007, 65, 168-73.	0.7	209
152	Suppression of inflammation by low-dose methotrexate is mediated by adenosine A2A receptor but not A3 receptor activation in thioglycollate-induced peritonitis. Arthritis Research and Therapy, 2006, 8, R53.	3.5	66
153	The inflammatory process of gout and its treatment. Arthritis Research and Therapy, 2006, 8, S3.	3.5	203
154	Adenosine A2A receptors play a role in the pathogenesis of hepatic cirrhosis. British Journal of Pharmacology, 2006, 148, 1144-1155.	5.4	209
155	Adenosine A2A receptors in diffuse dermal fibrosis: Pathogenic role in human dermal fibroblasts and in a murine model of scleroderma. Arthritis and Rheumatism, 2006, 54, 2632-2642.	6.7	122
156	Pharmacogenetics in the rheumatic diseases, from prêt-Ã-porter to haute couture. Nature Clinical Practice Rheumatology, 2006, 2, 2-3.	3.2	10
157	Tumor Necrosis Factor-α Prevents Desensitization of Gαs-Coupled Receptors by Regulating GRK2 Association with the Plasma Membrane. Molecular Pharmacology, 2006, 69, 1311-1319.	2.3	67
158	The Adenosine System Selectively Inhibits TLR-Mediated TNF-α Production in the Human Newborn. Journal of Immunology, 2006, 177, 1956-1966.	0.8	214
159	A prize for the foreignâ€born. FASEB Journal, 2006, 20, 1281-1283.	0.5	7
160	Do genetic variations in the adenosine pathway affect patient response to methotrexate?. Nature Clinical Practice Rheumatology, 2006, 2, 648-649.	3.2	2
161	Folic acid and folinic acid supplements and methotrexate therapy: Comment on the article by Morgan et al. Arthritis and Rheumatism, 2005, 52, 1338-1339.	6.7	1
162	Genetically based resistance to the antiinflammatory effects of methotrexate in the air-pouch model of acute inflammation. Arthritis and Rheumatism, 2005, 52, 2567-2575.	6.7	27

#	Article	IF	CITATIONS
163	An Interaction Between Genetic Factors and Gender Determines the Magnitude of the Inflammatory Response in the Mouse Air Pouch Model of Acute Inflammation. Inflammation, 2005, 29, 1-7.	3.8	15
164	Adenosine A2A Receptor Stimulation Increases Angiogenesis by Down-Regulating Production of the Antiangiogenic Matrix Protein Thrombospondin 1. Molecular Pharmacology, 2005, 67, 1406-1413.	2.3	369
165	Low-Dose Methotrexate: A Mainstay in the Treatment of Rheumatoid Arthritis. Pharmacological Reviews, 2005, 57, 163-172.	16.0	452
166	Response to RFP: "Rigorous Test of Intelligent Design― FASEB Journal, 2005, 19, 1936-1937.	0.5	0
167	Adenosine Receptors and Wound Healing. Scientific World Journal, The, 2004, 4, 1-8.	2.1	24
168	Adenosine A2Areceptor occupancy stimulates expression of proteins involved in reverse cholesterol transport and inhibits foam cell formation in macrophages. Journal of Leukocyte Biology, 2004, 76, 727-734.	3.3	70
169	Therapeutic cocktails for rheumatoid arthritis: The mixmaster's guide. Arthritis and Rheumatism, 2004, 50, 2041-2043.	6.7	8
170	Immunology for the rheumatologist. Rheumatic Disease Clinics of North America, 2004, 30, ix-x.	1.9	0
171	Adenosine A2A Receptor Activation Promotes Wound Neovascularization by Stimulating Angiogenesis and Vasculogenesis. American Journal of Pathology, 2004, 164, 1887-1892.	3.8	369
172	Adenosine: an endogenous regulator of innate immunity. Trends in Immunology, 2004, 25, 33-39.	6.8	1,042
173	Interferon-gamma impedes reverse cholesterol transport and promotes foam cell transformation in THP-1 human monocytes/macrophages. Medical Science Monitor, 2004, 10, BR420-5.	1.1	38
174	Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis and Rheumatism, 2003, 48, 240-247.	6.7	187
175	Bovine Thrombin and Systemic Autoimmunity. American Journal of Pathology, 2003, 162, 1389-1390.	3.8	3
176	Th1 Cytokines Regulate Adenosine Receptors and Their Downstream Signaling Elements in Human Microvascular Endothelial Cells. Journal of Immunology, 2003, 171, 3991-3998.	0.8	126
177	Adenosine Promotes Wound Healing and Mediates Angiogenesis in Response to Tissue Injury Via Occupancy of A2A Receptors. American Journal of Pathology, 2002, 160, 2009-2018.	3.8	202
178	Synergistic Up-Regulation of Vascular Endothelial Growth Factor Expression in Murine Macrophages by Adenosine A2A Receptor Agonists and Endotoxin. American Journal of Pathology, 2002, 160, 2231-2244.	3.8	440
179	Molecular action of methotrexate in inflammatory diseases. Arthritis Research, 2002, 4, 266.	2.0	368
180	Adenosine A2A receptor agonists promote more rapid wound healing than recombinant human platelet-derived growth factor (Becaplermin gel). Inflammation, 2002, 26, 19-24.	3.8	67

#	Article	IF	CITATIONS
181	Cyclooxygenase-2-selective inhibitors: translating pharmacology into clinical utility Cleveland Clinic Journal of Medicine, 2002, 69, SI13-SI13.	1.3	23
182	Inflammatory Cytokines Regulate Function and Expression of Adenosine A2A Receptors in Human Monocytic THP-1 Cells. Journal of Immunology, 2001, 167, 4026-4032.	0.8	223
183	Adenosine mediates the antiinflammatory effects of methotrexate as well as its toxicities. Drug Development Research, 2001, 52, 394-396.	2.9	1
184	Immune complexes and IFN-Î ³ decrease cholesterol 27-hydroxylase in human arterial endothelium and macrophages. Journal of Lipid Research, 2001, 42, 1913-1922.	4.2	70
185	Anti-Inflammatory Levels of Aspirin and Salicylate Inhibit Integrin-Dependent Human Neutrophil Aggregation and PMN Influx in COX 2- and NFkB (P105)-Knockout Mice. Medical Science Symposia Series, 2001, , 149-154.	0.0	Ο
186	Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: Evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. Arthritis and Rheumatism, 2000. 43. 656.	6.7	171
187	The mechanisms of methotrexate's action in the treatment of inflammatory disease. , 2000, , 65-82.		5
188	Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFÂB. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 6377-6381.	7.1	185
189	Millenial rheumatology. Current Rheumatology Reports, 1999, 1, 1-2.	4.7	0
190	Adenosine and Its Receptors During Inflammation. , 1999, , 259-274.		10
191	The Vascular Endothelium. , 1999, , 13-20.		3
192	Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides Journal of Clinical Investigation, 1998, 101, 295-300.	8.2	241
193	THE MECHANISM OF ACTION OF METHOTREXATE. Rheumatic Disease Clinics of North America, 1997, 23, 739-755.	1.9	213
194	Wound Healing Is Accelerated by Agonists of Adenosine A2 (Gαs-linked) Receptors. Journal of Experimental Medicine, 1997, 186, 1615-1620.	8.5	183
195	Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes. A mechanism for methotrexate-induced nodulosis in rheumatoid arthritis. Arthritis and Rheumatism, 1997, 40, 1308-1315.	6.7	13
196	Antifolate effect of methotrexate: Comment on the article by cronstein. Arthritis and Rheumatism, 1997, 40, 1545-1546.	6.7	0
197	Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes: A mechanism for methotrexate-induced nodulosis in rheumatoid arthritis. Arthritis and Rheumatism, 1997, 40, 1308-1315.	6.7	135
198	TSG-6, a glycoprotein associated with arthritis, and its ligand hyaluronan exert opposite effects in a murine model of inflammation. Pflugers Archiv European Journal of Physiology, 1996, 431, R225-R226.	2.8	20

#	Article	IF	CITATIONS
199	Purinergic mechanisms in inflammation. Drug Development Research, 1996, 39, 426-435.	2.9	18
200	Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis and Rheumatism, 1996, 39, 1951-1960.	6.7	237
201	Adenosine A2 Receptor Occupancy Regulates Stimulated Neutrophil Function via Activation of a Serine/Threonine Protein Phosphatase. Journal of Biological Chemistry, 1996, 271, 17114-17118.	3.4	88
202	Identification of C1q as the heat-labile serum cofactor required for immune complexes to stimulate endothelial expression of the adhesion molecules E-selectin and intercellular and vascular cell adhesion molecules 1 Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 8378-8382.	7.1	136
203	The antiinflammatory effects of an adenosine kinase inhibitor are mediated by adenosine. Arthritis and Rheumatism, 1995, 38, 1040-1045.	6.7	123
204	Targets for Antiinflammatory Drugs. Annual Review of Pharmacology and Toxicology, 1995, 35, 449-462.	9.4	65
205	Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils Journal of Clinical Investigation, 1995, 96, 994-1002.	8.2	290
206	The Antiinflammatory Effects of Methotrexate are Mediated by Adenosine. Advances in Experimental Medicine and Biology, 1995, 370, 411-416.	1.6	57
207	Clinical use of methylprednisolone sodium succinate: a review. Current Therapeutic Research, 1995, 56, 1-15.	1.2	3
208	Nonsteroidal antiinflammatory agents inhibit stimulated neutrophil adhesion to endothelium: Adenosine dependent and independent mechanisms. Inflammation, 1994, 18, 323-335.	3.8	84
209	Intravascular Neutrophil Activation in Systemic Lupus Erythematosus (SLE): Dissociation between Increased Expression of CD11b/CD18 and Diminished Expression of L-Selectin on Neutrophils from Patients with Active SLE. Clinical Immunology and Immunopathology, 1994, 71, 281-286.	2.0	46
210	Adhesion Molecules in Inflammation. BioDrugs, 1994, 1, 323-326.	0.7	3
211	The adhesion molecules of inflammation. Arthritis and Rheumatism, 1993, 36, 147-157.	6.7	238
212	The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation Journal of Clinical Investigation, 1993, 92, 2675-2682.	8.2	594
213	A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1 Proceedings of the National Academy of Sciences of the United States of America. 1992. 89. 9991-9995.	7.1	702
214	Age-related changes in neutrophil structure and function. Mechanisms of Ageing and Development, 1992, 64, 303-313.	4.6	42
215	Molecular mechanism of methotrexate action in inflammation. Inflammation, 1992, 16, 411-423.	3.8	54
216	Correlation of the conformation of a modified ribonuclease octapeptide, homologous to peptide T, with its ability to induce CD4-dependent monocyte chemotaxis. The Protein Journal, 1992, 11, 475-481.	1.1	1

#	Article	IF	CITATIONS
217	Neuropeptides and inflammation. A somatostatin analog as a selective antagonist of neutrophil activation by substance P. Arthritis and Rheumatism, 1992, 35, 369-375.	6.7	69
218	Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 2441-2445.	7.1	317
219	Transforming growth factor beta 1, a potent chemoattractant for human neutrophils, bypasses classic signal-transduction pathways Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 6805-6809.	7.1	195
220	Adenosine and Host Defense. , 1990, , 475-500.		4
221	The adenosine/neutrophil paradox resolved: human neutrophils possess both A1 and A2 receptors that promote chemotaxis and inhibit O2 generation, respectively Journal of Clinical Investigation, 1990, 85, 1150-1157.	8.2	349
222	Occupancy of adenosine receptors on human neutrophils inhibits respiratory burst stimulated by ingestion of complement-coated particles and occupancy of chemoattractant but not Fc receptors. Inflammation, 1989, 13, 591-599.	3.8	16
223	Adenosine, a cytoprotective autocoid: effects of adenosine on neutrophil plasma membrane viscosity and chemoattractant receptor display. Biochimica Et Biophysica Acta - Biomembranes, 1989, 987, 176-180.	2.6	12
224	Adenosine promotes neutrophil chemotaxis Journal of Experimental Medicine, 1988, 167, 1186-1194.	8.5	103
225	Engagement of adenosine receptors inhibits hydrogen peroxide (H2O2â^) release by activated human neutrophils. Clinical Immunology and Immunopathology, 1987, 42, 76-85.	2.0	70
226	Serum complement values (C3 and C4) to differentiate between systemic lupus activity and pre-eclampsia. American Journal of Medicine, 1986, 81, 194-200.	1.5	109
227	Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells Journal of Clinical Investigation, 1986, 78, 760-770.	8.2	386
228	Adenosine Modulates the Generation of Superoxide Anion by Stimulated Human Neutrophils via Interaction with a Specific Cell Surface Receptora. Annals of the New York Academy of Sciences, 1985, 451, 291-301.	3.8	32
229	Adenosine deaminase is not required for the generation of superoxide anion. Clinical Immunology and Immunopathology, 1984, 30, 495-499.	2.0	7
230	Systemic lupus erythematosus in a patient with reiter's syndrome. Arthritis and Rheumatism, 1983, 26, 1405-1408.	6.7	4
231	Adenosine: a physiological modulator of superoxide anion generation by human neutrophils Journal of Experimental Medicine, 1983, 158, 1160-1177.	8.5	451
232	Adenosine Receptors: Therapeutic Aspects for Inflammatory and Immune Diseases. , 0, , 186-197.		0